Foster Healthcare

fosterhealthcare.org

Foster Healthcare is a C.H.A.P. Accredited Home Health provider with a focus on patient centered practices. INcompass - our industry first Transitional Care Program - leverages comprehensive care coordination with the latest Wireless Tele-Health technology to keep stakeholders informed of changes in patient condition. Our Care Team approach includes Nurses, Therapists, Social Workers and Certified Home Health Aides to keep patients out of the Hospital and in their homes where they belong.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

news image

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

Pharmacy Market

HKSTP AND BOEHRINGER INGELHEIM VENTURE FUND LAUNCH CO-INCUBATION PROGRAMME TO FAST-TRACK R&D IN INFECTIOUS DISEASES AND IMMUNOLOGY

BIVF | June 18, 2022

news image

Hong Kong Science and Technology Parks Corporation is partnering global research-driven biopharmaceutical leader, Boehringer Ingelheim Venture Fund Limited in a strategic co-incubation collaboration to promote and nurture startups on research and development for infectious diseases and immunology. HKSTP is dedicated to collaborating with sector leaders in building the strongest I&T eco-system to help startups via business development, mentorship and investment initiatives. In ...

Read More

Business Insights

COSETTE PHARMACEUTICALS ACQUIRES INTRAROSA® FROM ENDOCEUTICS, INC.

Businesswire | June 12, 2023

news image

Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of the global rights to Intrarosa® from Endoceutics, Inc., a subsidiary of Endorecherche, Inc. The transaction includes 108 issued and pending patents across the globe with the latest expiring in 2033 including 3 Orange Book listed patents. Intrarosa® is currently available in almost all maj...

Read More

Business Insights

TFF PHARMACEUTICALS EXPANDS R&D OPERATIONS WITH NEW AUSTIN FACILITY

TFF Pharmaceuticals, Inc. | July 16, 2022

news image

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. The new facility of over 3,500 square feet significantly increases TFF’s total lab space, adding a dedicated lab for downs...

Read More
news image

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

news image

Pharmacy Market

HKSTP AND BOEHRINGER INGELHEIM VENTURE FUND LAUNCH CO-INCUBATION PROGRAMME TO FAST-TRACK R&D IN INFECTIOUS DISEASES AND IMMUNOLOGY

BIVF | June 18, 2022

Hong Kong Science and Technology Parks Corporation is partnering global research-driven biopharmaceutical leader, Boehringer Ingelheim Venture Fund Limited in a strategic co-incubation collaboration to promote and nurture startups on research and development for infectious diseases and immunology. HKSTP is dedicated to collaborating with sector leaders in building the strongest I&T eco-system to help startups via business development, mentorship and investment initiatives. In ...

Read More
news image

Business Insights

COSETTE PHARMACEUTICALS ACQUIRES INTRAROSA® FROM ENDOCEUTICS, INC.

Businesswire | June 12, 2023

Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of the global rights to Intrarosa® from Endoceutics, Inc., a subsidiary of Endorecherche, Inc. The transaction includes 108 issued and pending patents across the globe with the latest expiring in 2033 including 3 Orange Book listed patents. Intrarosa® is currently available in almost all maj...

Read More
news image

Business Insights

TFF PHARMACEUTICALS EXPANDS R&D OPERATIONS WITH NEW AUSTIN FACILITY

TFF Pharmaceuticals, Inc. | July 16, 2022

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. The new facility of over 3,500 square feet significantly increases TFF’s total lab space, adding a dedicated lab for downs...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us